KR20220066075A - T-세포 조절 폴리펩타이드 및 이의 사용 방법 - Google Patents

T-세포 조절 폴리펩타이드 및 이의 사용 방법 Download PDF

Info

Publication number
KR20220066075A
KR20220066075A KR1020227009918A KR20227009918A KR20220066075A KR 20220066075 A KR20220066075 A KR 20220066075A KR 1020227009918 A KR1020227009918 A KR 1020227009918A KR 20227009918 A KR20227009918 A KR 20227009918A KR 20220066075 A KR20220066075 A KR 20220066075A
Authority
KR
South Korea
Prior art keywords
polypeptide
seq
amino acid
hla
tmp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020227009918A
Other languages
English (en)
Korean (ko)
Inventor
로날드 디. 3세 사이델
로돌포 제이. 차파로
존 에프. 로스
사소 세메르스키
Original Assignee
큐 바이오파마, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 큐 바이오파마, 인크. filed Critical 큐 바이오파마, 인크.
Publication of KR20220066075A publication Critical patent/KR20220066075A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020227009918A 2019-09-20 2020-09-17 T-세포 조절 폴리펩타이드 및 이의 사용 방법 Withdrawn KR20220066075A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962903441P 2019-09-20 2019-09-20
US62/903,441 2019-09-20
US202062990693P 2020-03-17 2020-03-17
US62/990,693 2020-03-17
US202063048561P 2020-07-06 2020-07-06
US63/048,561 2020-07-06
PCT/US2020/051255 WO2021055594A1 (en) 2019-09-20 2020-09-17 T-cell modulatory polypeptides and methods of use thereof

Publications (1)

Publication Number Publication Date
KR20220066075A true KR20220066075A (ko) 2022-05-23

Family

ID=74884186

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227009918A Withdrawn KR20220066075A (ko) 2019-09-20 2020-09-17 T-세포 조절 폴리펩타이드 및 이의 사용 방법

Country Status (11)

Country Link
US (2) US20220143063A1 (https=)
EP (1) EP4030897A4 (https=)
JP (1) JP7756072B2 (https=)
KR (1) KR20220066075A (https=)
CN (1) CN114423284A (https=)
AU (1) AU2020348373A1 (https=)
CA (1) CA3146591A1 (https=)
IL (1) IL290635A (https=)
MX (1) MX2022003367A (https=)
TW (1) TW202126683A (https=)
WO (1) WO2021055594A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116970059A (zh) 2016-12-22 2023-10-31 库尔生物制药有限公司 T细胞调节性多聚体多肽及其使用方法
IL269000B2 (en) 2017-03-15 2024-06-01 Cue Biopharma Inc Methods for modulating an immune response
TW201920249A (zh) 2017-09-07 2019-06-01 美商信號生物製藥公司 具有結合位點之t細胞調節多聚體多肽及其使用方法
TWI856047B (zh) * 2018-12-19 2024-09-21 美商信號生物製藥公司 多聚體ｔ細胞調節多肽及其使用方法
US12453774B2 (en) * 2019-11-07 2025-10-28 Genoimmune Therapeutics Co., Ltd. Tumor immunotherapy polypeptide and application thereof
TW202208395A (zh) 2020-05-12 2022-03-01 美商信號生物製藥公司 多聚體ｔ細胞調節多肽及其使用方法
EP4211149A4 (en) 2020-09-09 2024-10-09 Cue Biopharma, Inc. MULTIMERIC POLYPEPTIDES MODULATING MHC CLASS II T CELLS FOR THE TREATMENT OF TYPE 1 DIABETES MELLITUS (T1D) AND METHODS OF USE THEREOF
US11421015B2 (en) 2020-12-07 2022-08-23 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
US11058751B1 (en) 2020-11-20 2021-07-13 Think Therapeutics, Inc. Compositions for optimized RAS peptide vaccines
CN116710115A (zh) 2020-11-20 2023-09-05 思维疗法股份有限公司 用于优化的肽疫苗的组合物和方法
US12275766B2 (en) * 2020-12-23 2025-04-15 Janssen Biotech, Inc. Neoantigen peptide mimics
JP2024512470A (ja) * 2021-03-19 2024-03-19 キュー バイオファーマ， インコーポレイテッド Ｔ細胞調節ポリペプチド及びその使用方法
US11464842B1 (en) 2021-04-28 2022-10-11 Think Therapeutics, Inc. Compositions and method for optimized peptide vaccines using residue optimization
CN119095882A (zh) * 2022-04-07 2024-12-06 Cue生物制药股份有限公司 免疫细胞结合多肽
CN115820736B (zh) * 2022-12-08 2024-05-10 西南大学 家蚕丝胶蛋白Ser4在提高蚕丝性能中的应用及其方法
WO2024264007A2 (en) * 2023-06-23 2024-12-26 Cue Biopharma, Inc. T-cell modulatory polypeptides and methods of use thereof
WO2024264004A2 (en) * 2023-06-23 2024-12-26 Cue Biopharma, Inc. T-cell modulatory polypeptides and methods of use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3157552T3 (pl) * 2014-06-18 2020-05-18 Albert Einstein College Of Medicine Polipeptydy syntac i ich zastosowania
CN115873129A (zh) * 2015-03-23 2023-03-31 约翰·霍普金斯大学 由体细胞突变基因编码的hla限制性表位
EP3408279A1 (en) * 2016-01-27 2018-12-05 CSL Behring Lengnau AG Recombinant igg fc multimers
CA3014458A1 (en) * 2016-03-02 2017-09-08 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
AU2017225787B2 (en) * 2016-03-03 2021-09-23 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
CA3019005A1 (en) * 2016-05-18 2017-11-23 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
CN116970059A (zh) * 2016-12-22 2023-10-31 库尔生物制药有限公司 T细胞调节性多聚体多肽及其使用方法
US11851471B2 (en) * 2017-01-09 2023-12-26 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
IL269000B2 (en) * 2017-03-15 2024-06-01 Cue Biopharma Inc Methods for modulating an immune response
TW201920249A (zh) * 2017-09-07 2019-06-01 美商信號生物製藥公司 具有結合位點之t細胞調節多聚體多肽及其使用方法
WO2019139896A1 (en) * 2018-01-09 2019-07-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
WO2021230247A1 (ja) * 2020-05-12 2021-11-18 大日本住友製薬株式会社 癌を処置するための医薬組成物

Also Published As

Publication number Publication date
IL290635A (en) 2022-04-01
CN114423284A (zh) 2022-04-29
TW202126683A (zh) 2021-07-16
US20220143063A1 (en) 2022-05-12
JP7756072B2 (ja) 2025-10-17
US20250120996A1 (en) 2025-04-17
CA3146591A1 (en) 2021-03-25
EP4030897A4 (en) 2023-10-18
WO2021055594A1 (en) 2021-03-25
MX2022003367A (es) 2022-04-11
AU2020348373A1 (en) 2022-02-24
JP2022548472A (ja) 2022-11-21
EP4030897A1 (en) 2022-07-27

Similar Documents

Publication Publication Date Title
US20220143063A1 (en) T-cell modulatory polypeptides and methods of use thereof
JP7403703B2 (ja) 多量体ポリペプチド、ホモ二量体及び医薬組成物
TWI856047B (zh) 多聚體ｔ細胞調節多肽及其使用方法
US20240067700A1 (en) T-cell modulatory polypeptides and methods of use thereof
CN113286621A (zh) 多聚体t细胞调节多肽及其使用方法
US20240376177A1 (en) Multimeric t-cell modulatory polypeptides and methods of use thereof
US20260109958A1 (en) T-Cell Modulatory Polypeptides and Methods of Use Thereof
US20230241192A1 (en) Multimeric t-cell modulatory polypeptides and methods of use thereof
HK40060108A (en) Multimeric t-cell modulatory polypeptides and methods of use thereof
HK40102439A (zh) T细胞调节性多聚体多肽及其使用方法
HK40102809A (zh) T细胞调节性多聚体多肽及其使用方法
HK40109852A (zh) T细胞调节性多聚体多肽及其使用方法
HK40102438A (zh) T细胞调节性多聚体多肽及其使用方法
HK40102436A (zh) T细胞调节性多聚体多肽及其使用方法
EA049816B1 (ru) Модулирующие т-клетки мультимерные полипептиды и способы их применения
HK40089384A (zh) 多聚体t细胞调节多肽及其使用方法
HK40060108B (zh) 多聚体t细胞调节多肽及其使用方法

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

B11 Application withdrawn

Free format text: ST27 STATUS EVENT CODE: N-1-6-B10-B11-NAP-PC1202 (AS PROVIDED BY THE NATIONAL OFFICE)

PC1202 Submission of document of withdrawal before decision of registration

St.27 status event code: N-1-6-B10-B11-nap-PC1202